Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more

Welcome back to another edition of Endpoints Weekly! For those that had time off for Presidents’ Week, we hope you had a restful vacation. If you missed any of the headlines, we had a lot ...